drug · oligonucleotide
eplontersen sodium
Marketedupdated 6mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Oligonucleotide drug with a maximum clinical stage of Approval (across all indications), with an approval for familial amyloid neuropathy and polyneuropathy and 1 investigational indication.
targets
Transthyretin mRNA
all catalysts(5)
approval · 5
Dec 21, 2023
approval
$AZN185.48-0.69%
WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — FDA approval
eplontersen sodium
→
Sep 25, 2024
approval
$AZN185.48-0.69%
WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — FDA approval
eplontersen sodium
→
Apr 18, 2025
approval
$AZN185.48-0.69%
WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — FDA approval
eplontersen sodium
→
Dec 17, 2025
approval
$AZN185.48-0.69%
WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — FDA approval
eplontersen sodium
→
Apr 15, 2026
approval
$AZN185.48-0.69%
WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — FDA approval
eplontersen sodium
→
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 21, 2028
~2.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Aug 25, 2034compositionUS 10683499
- May 1, 2034compositionUS 9127276
- May 1, 2034compositionUS 9181549
- Apr 1, 2026compositionUS 8101743
FDA exclusivities (2)
- Dec 21, 2030ODE-461Orphan Drug (7y)4.1y
- Dec 21, 2028NCENew Chemical Entity (5y)2.1y
News(10)
- AstraZeneca’s bruising summer raises the stakes for 2027When one of AstraZeneca’s medicines, Wainua, failed a major late-stage heart disease trial in July, it was a jarring setback for a drugmaker whose research pipeline had become one of the most admir…endpoints · 14d ago
- GSK, Ionis win FDA nod for hepatitis B functional cure that controls virus after treatmentHibsago’s approval—a functional cure for certain patients with a hepatitis B infection—further validates Ionis Pharmaceuticals’ antisense platform, which has already generated two other new drug ap…biospace · 21d ago
- Alnylam bulls and bears fight it out after business-shaking guidance cutWhile Alnylam’s recent reduced revenue guidance spooked investors, analysts remain broadly bullish on the biotech’s commercial prospects.biospace · 23d ago
- AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitroAstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, following the Phase 3 failure of its Ionis-partnered Wainua in…biospace · 27d ago
- Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALSUlefnersen, an RNA-targeted therapy being developed by Ionis Pharmaceuticals and Otsuka Pharmaceutical, improved measurements of functional impairment and survival in patients with a rare, genetic…biospace · 1mo ago
- 5 biotechs braving the commercial waters with product launchesA growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.biospace · 1mo ago
- Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’After the failure of Novo Nordisk’s IL-6 inhibitor ziltivekimab sent waves through the industry, the company has terminated two other studies of the asset, bringing the total number of high-profile…biospace · 2mo ago
- Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN dealsNovartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines scores early FDA approval for groundbrea…biospace · 2mo ago
- STAT+: Trump strikes nine more deals with drugmakers to lower pricesPresident Trump on Monday announced the next round of pricing deals with drugmakers, with nine new companies making such agreements.stat · 2mo ago
- ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CMAs AstraZeneca appears to close the book on a combo approach following the phase 3 failure of its Ionis-partnered Wainua, several analysts contend it’s too early to count out Alnylam’s silencing dr…fiercebiotech · 2mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that